Eupraxia Pharmaceuticals announced encouraging data from its ongoing Phase 1b/2a RESOLVE trial evaluating EP-104GI for eosinophilic esophagitis (EoE). The data showed that patients receiving 20 injections of EP-104GI experienced significant improvements in the Eosinophilic Esophagitis Endoscopic Reference Score (EREFS), indicating reduced inflammation and fibrosis in the esophagus. This dosing regimen is now being studied in the placebo-controlled Phase 2b trial, with top-line results expected in Q4 2026. These findings suggest EP-104GI could offer a promising new treatment for EoE, a condition causing esophageal inflammation and swallowing difficulties.
Across Protocol suffered a loss of less than $4 million after an attacker fabricated $41.7 million in fake Solana deposit events using 1,627 single-use wallets. The attack targeted 18 chains, but Risk Labs' relayer paid out only $4.5 million on 581 f...
Liberty Global's Q2 update shows mixed headline results but improved underlying trends, especially at VodafoneZiggo. The company is advancing its plan to separate Ziggo Group by 2027 and is converting portfolio assets into cash, providing strong down...
Crocs is considered fairly valued at $125, driven by stable operations, high gross margins, and strong international expansion. International sales are expected to grow from 41% in 2023 to 48.6% by 2025, supported by direct-to-consumer sales and new ...
Arbitrum has launched an upgrade that supports multiple virtual machines, allowing developers to write smart contracts in languages like Rust and C++ beyond just Solidity. This broadens development options and reduces friction for teams preferring di...
Bitcoin options markets remain bullish with call options dominating both open interest and trading volume, despite a 3.14% decline in total open interest to $33.20 billion. Calls make up 66.24% of outstanding contracts, signaling traders' continued o...
